News | 28 October 2026
The approval makes Sunharbo the first Factor XIa inhibitor approved worldwide
The training will extend beyond doctors to include endoscopy technicians and nursing professionals, recognising the importance of coordinated
The progression-free survival benefit was consistent across all prespecified subgroups
Commercialisation in each market will be subject to approval by the respective national regulatory authority
The ruling significantly expands the scope of the restrictions
The collaboration is designed to create opportunities for international market access while exploring potential investment and business partnerships
The new ingredient aims to address a persistent challenge for the personal care industry
Panelists include Parizad A. Elchidana, ACG World; Dr. Kiran Marthak, Veeda Life Sciences; Dr. Ravikrishna Chebolu, CSIR Innovation Complex; Dr. Ganesh Sangle, Alkem Laboratories; Sachin Mishra, Akumentis Healthcare; and Rahul Koul, Indian Pharma Post
Prolific has reported a productivity milestone of 21 grams per litre in a 15-day intensified fed-batch run for a monoclonal antibody
BRINSUPRI is designed to target an underlying driver of the disease rather than simply address its symptoms.
The updated recommendation adds to the drug’s existing Category 2A designation for metastatic cutaneous squamous cell carcinoma
Lysine is one of the most limiting amino acids in ruminant nutrition and a critical driver of animal performance
Rewin Health is also working with healthcare institutions, special schools and government bodies to integrate digital therapeutics into mainstream support systems
New milestone in local radioisotope production aims to support PET imaging
Nearly 1,800 adults enrolled across 109 sites in North America and Europe
Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma
Subscribe To Our Newsletter & Stay Updated
